Needham & Company LLC set a $95.00 price objective on Sage Therapeutics, Inc. (NASDAQ:SAGE) in a research report released on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on SAGE. Canaccord Genuity set a $110.00 price target on shares of Sage Therapeutics and gave the company a buy rating in a research note on Wednesday, April 12th. Bank of America Corporation started coverage on shares of Sage Therapeutics in a research note on Friday, May 12th. They set a buy rating and a $85.00 price target on the stock. ValuEngine raised shares of Sage Therapeutics from a sell rating to a hold rating in a research note on Friday, June 2nd. Cowen and Company started coverage on shares of Sage Therapeutics in a research note on Monday, June 12th. They set an outperform rating and a $95.00 price target on the stock. Finally, BidaskClub raised shares of Sage Therapeutics from a buy rating to a strong-buy rating in a research note on Tuesday, June 13th. Four analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $88.36.

Sage Therapeutics (NASDAQ:SAGE) traded up 1.868% during midday trading on Friday, hitting $88.625. The stock had a trading volume of 72,219 shares. The firm has a 50 day moving average price of $81.06 and a 200 day moving average price of $68.74. Sage Therapeutics has a one year low of $35.02 and a one year high of $89.16. The stock’s market cap is $3.31 billion.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.63) by $0.25. During the same quarter last year, the company earned ($1.08) EPS. Equities analysts expect that Sage Therapeutics will post ($7.23) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Needham & Company LLC Analysts Give Sage Therapeutics, Inc. (NASDAQ:SAGE) a $95.00 Price Target” was reported by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/07/needham-company-llc-analysts-give-sage-therapeutics-inc-nasdaqsage-a-95-00-price-target.html.

Institutional investors have recently made changes to their positions in the stock. FMR LLC boosted its position in shares of Sage Therapeutics by 0.3% in the first quarter. FMR LLC now owns 5,590,527 shares of the biopharmaceutical company’s stock worth $397,319,000 after buying an additional 15,451 shares during the last quarter. BlackRock Inc. boosted its position in shares of Sage Therapeutics by 10,082.5% in the first quarter. BlackRock Inc. now owns 2,863,124 shares of the biopharmaceutical company’s stock worth $203,482,000 after buying an additional 2,835,006 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Sage Therapeutics by 10.8% in the first quarter. Vanguard Group Inc. now owns 2,691,275 shares of the biopharmaceutical company’s stock worth $191,269,000 after buying an additional 261,759 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Sage Therapeutics by 189.3% in the first quarter. Bank of New York Mellon Corp now owns 2,056,895 shares of the biopharmaceutical company’s stock worth $146,183,000 after buying an additional 1,345,829 shares during the last quarter. Finally, Palo Alto Investors LLC boosted its position in shares of Sage Therapeutics by 9.1% in the first quarter. Palo Alto Investors LLC now owns 1,101,951 shares of the biopharmaceutical company’s stock worth $78,316,000 after buying an additional 92,021 shares during the last quarter.

About Sage Therapeutics

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.